Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2017

View Archived Issues

Health Canada approves Roche's cobas EGFR Mutation Test v2

twoXAR reports promising results for liver cancer candidate TXR-311 in cell-based assays

INCJ, Takeda and Medipal announce plans for new company Scohia Pharma

PeptiMimesis receives second tranche of investment

Aeolus reports potential of AEOL-20415 for cystic fibrosis

Preclinical and first patient evaluation of (99m)Tc-PSMA-I&S in prostate cancer

Catalyst Pharmaceuticals reports data on Firdapse in MuSK antibody-positive myasthenia gravis

First-in-human data for venetoclax in patients with relapsed or refractory non-Hodgkin's lymphoma

Mateon reports third cohort data from phase Ib study of OXi-4503 in AML and MDS

Schizophrenia research at Feinstein Institute for Medical Research supported by NIH grant

MAGEL2 gene nonsense mutation found in a patient with Opitz-C syndrome

Therapix and Rafa sign a memorandum of understanding for venture formation

Wakamoto completes Japanese phase I trial of WP-1303

Peptonic Medical refocuses development of Vagitocin based on initial phase IIb results

Servier to cease European marketing of Protelos/Osseor

European Commission approves Cinryze to prevent and treat HAE attacks in children

GSK seeks U.S. approval for use of Fluarix Quadrivalent in infants age 6 months and older

Oxidized CaMKII inhibition could alleviate asthma

Glycyx and Valeant agree to licensing deal for methylnaltrexone bromide in oncology

Trovagene and Nerviano sign licensing agreement for NMS-1286937

Medivir out-licenses commercial rights in order to focus fully on R&D

CD47 determined as a poor prognostic factor for multiple myeloma patients

Clarivate Analytics launches Drug Research Advisor with target identification app

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...